Analysis of the marketing of rare disease drugs in China based on <italic style="font-style: italic">the First Batch of Rare Disease Catalog</italic>

PENG Feifei; JIANG Junhao; BAO Yujian; ZHENG Hang

doi:10.6039/j.issn.1001-0408.2024.11.02

您当前的位置：

首页 >

文章列表页 >

Analysis of the marketing of rare disease drugs in China based on the First Batch of Rare Disease Catalog

更新时间：2024-06-11

- Analysis of the marketing of rare disease drugs in China based on the First Batch of Rare Disease Catalog
- ZHONGGUO YAOFANG Vol. 35, Issue 11, Pages: 1291-1295(2024)
- 作者机构：
  
  重庆医科大学药学院，重庆　400016
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.11.02
  CLC： R95
- Published：15 June 2024，
  
  Received：02 November 2023，
  
  Revised：25 March 2024，
扫描看全文
彭菲菲,蒋君好,鲍宇健等.基于《第一批罕见病目录》的我国罕见病药物上市情况分析 ^Δ[J].中国药房,2024,35(11):1291-1295.

PENG Feifei,JIANG Junhao,BAO Yujian,et al.Analysis of the marketing of rare disease drugs in China based on the First Batch of Rare Disease Catalog[J].ZHONGGUO YAOFANG,2024,35(11):1291-1295.
彭菲菲,蒋君好,鲍宇健等.基于《第一批罕见病目录》的我国罕见病药物上市情况分析 ^Δ[J].中国药房,2024,35(11):1291-1295. DOI： 10.6039/j.issn.1001-0408.2024.11.02.

PENG Feifei,JIANG Junhao,BAO Yujian,et al.Analysis of the marketing of rare disease drugs in China based on the First Batch of Rare Disease Catalog[J].ZHONGGUO YAOFANG,2024,35(11):1291-1295. DOI： 10.6039/j.issn.1001-0408.2024.11.02.

摘要

目的

考察我国罕见病药物的上市现状、一般特征以及时间发展趋势。

方法

基于《第一批罕见病目录》收纳的121种罕见病，从国家药品监督管理局药品审评中心和药智网数据库中获取相应适应证药物的名称和批准上市信息，提取相关特征变量进行描述性统计分析。

结果

截至2022年12月31日，该目录收纳的121种罕见病中，有治疗药物上市的仅有32种，共涉及79个罕见病药物。其中，46.84%的药物是国产药，有88.61%的药物被批准成人和儿童都可用；化药占比为67.09%，注射剂占比为59.49%；按解剖学、治疗学及化学分类系统（ATC）分类，A类（消化系统用药）是最多的，占比为20.25%。每年上市的罕见病药物数量在2021年最多，2018－2021年总体呈上升趋势，2022年呈下降趋势。每年上市的罕见病药物中，按ATC分类，L类（抗肿瘤药及免疫用药）在2021年上市的数量最多，为5个；按剂型分类，口服制剂在2022年上市的数量最多，注射剂在2021年上市的数量最多。

结论

近年来我国罕见病药物上市数量不断增长，但是还远不能满足患者需求，并且上市的国产罕见病药物还非常缺乏。应进一步加快罕见病药物的研发，促进罕见病药物的进口与仿制。

Abstract

OBJECTIVE

To investigate the marketing status， general characteristics， and time trends of rare disease drugs in China.

METHODS

Based on 121 kinds of rare diseases included in

the First Batch of Rare Disease Catalog

， the names and marketing approval information of corresponding drugs with indications were obtained from the databases of the Center for Drug Evaluation， National Medical Products Administration and Yaozhi.com， and the relevant characteristic variables were extracted for descriptive statistical analysis.

RESULTS

As of December 31， 2022， only 32 of 121 rare diseases have therapeutic drugs available for treatment on the market in China， and 79 rare disease drugs have been approved. Among them， 46.84% of the drugs are domestic drugs， 88.61% of the drugs are approved for use in both adults and children； 67.09% are chemicals and 59.49% are injections. According to the ATC classification， Category A （digestive system drugs） is the most， accounting for 20.25%. The number of rare disease drugs on the market each year is the highest in 2021， with an overall upward trend from 2018 to 2021 and a downward trend in 2022. Among rare disease drugs on the market each year， according to the ATC classification， the number of Category L （antineoplastics and immune inhibitors） will be the largest in 2021， being 5. By dosage form， oral medicines were marketed in the largest number in 2022， and injectable medicines in 2021.

CONCLUSIONS

In recent years， the number of approved rare disease drugs in China has been continuously increasing， but it is still far from meeting the needs of patients， and there is still a lack of domestically approved rare disease drugs. We should further accelerate the research and development of rare disease drugs， and promote the import and replication of rare disease drugs.

关键词

罕见病罕见病药物第一批罕见病目录上市情况发展趋势

Keywords

rare disease drugsthe first batch of rare disease catalogmarketingtrend

references

王雪，赵聪，许淑红，等. 我国罕见病用药可及性现状分析[J]. 中国临床药理学杂志，2021，37（8）：1026-1032.

WANG X，ZHAO C，XU S H，et al. Analysis of the rare disease drugs availability in China[J]. Chin J Clin Pharmacol，2021，37（8）：1026-1032.

刘鑫，李建涛，张鹏霄，等. 中国罕见病药物现状及与国外对比分析研究[J]. 中国药学杂志，2019，54（10）：839-846.

LIU X，LI J T，ZHANG P X，et al. Current status of orphan drugs in China and comparative analysis with foreign countries[J]. Chin Pharm J，2019，54（10）：839-846.

国家卫生健康委员会医政医管局.关于公布第一批罕见病目录的通知[EB/OL].（2018-05-11）[2019-12-30]. http：//www.gov.cn/xxgk/pages/viewdocument.jsp?dispatch- Date=http://www.gov.cn/xxgk/pages/viewdocument.jsp?dispatch-Date=＆staticUrl=/yzygj/s7659/201806/.

Medical Administration Bureau of the National Health Commission. Notice on the publication of the first list of rare diseases[EB/OL]. （2018-05-11）[2019-12-30]. http：//www.gov.cn/xxgk/pages/viewdocument.jspdispatchDate=http://www.gov.cn/xxgk/pages/viewdocument.jspdispatchDate=＆staticUrl=/yzygj/s7659/201806/.

吴诗瑜，张勘. 中国建立罕见病研究和防治策略的机遇与未来挑战[J]. 上海医药，2011，32（10）：502-504.

WU S Y，ZHANG K. Opportunities and future challenges of establishing research and prevention strategies for rare diseases in China[J]. Shanghai Med Pharm J，2011，32（10）：502-504.

邵文斌，李杨阳，王菲，等. 中国罕见病药品可及性现状及解决建议[J]. 中国食品药品监管，2019（2）：8-15.

SHAO W B，LI Y Y，WANG F，et al. Current situation and solutions of drug accessibility for rare diseases in China[J]. China Food Drug Adm Mag，2019（2）：8-15.

国家药品监督管理局，国家卫生健康委员会.关于优化药品注册审评审批有关事宜的公告[EB/OL].（2018-05-23）[2020-12-22]. https：//www.nmpa.gov.cn/zhuanti/ypqxgg/ggzhcfg/20180523110601517.htmlhttps://www.nmpa.gov.cn/zhuanti/ypqxgg/ggzhcfg/20180523110601517.html．

National Medical Products Administration，National Health Commission. Announcement on optimizing matters related to drug registration review and approval[EB/OL]. （2018-05-23）[2020-12-22]. https：//www.nmpa.gov.cn/zhuanti/ypqxgg/ggzhcfg/20180523110601517.htmlhttps://www.nmpa.gov.cn/zhuanti/ypqxgg/ggzhcfg/20180523110601517.html．

中共中央办公厅，国务院办公厅.关于深化审评审批制度改革鼓励药品医疗器械创新的意见[EB /OL]. （2017-10-08）[2020-12-22]. http：//www.gov.cn/zhengce/2017-10/08/content_5230105.htmhttp://www.gov.cn/zhengce/2017-10/08/content_5230105.htm．

General Office of the CPC Central Committee，General Office of the State Council. Opinions on deepening the reform of the review and approval system and encouraging innovation of pharmaceutical and medical devices[EB/OL].（2017-10-08）[2020-12-22]. http：//www.gov.cn/zhengce/2017-10/08/content_5230105.htmhttp://www.gov.cn/zhengce/2017-10/08/content_5230105.htm．

周盛明，李嘉瑶，周静，等. 中国罕见病用药可负担性评价[J]. 中国药业，2021，30（1）：9-15.

ZHOU S M，LI J Y，ZHOU J，et al. Evaluation of the affordability of orphan medical products in China[J]. China Pharm，2021，30（1）：9-15.

朱楚玉，孙维阳，常峰，等. 我国罕见病药品价格水平和可负担性研究[J]. 中国药房，2021，32（8）：897-903.

ZHU C Y，SUN W Y，CHANG F，et al. Study on the price and affordability of rare disease drugs in China[J]. China Pharm，2021，32（8）：897-903.

俞颖慧，杨树俊，周斌. 我国罕见病药物优先审评审批情况简析[J]. 中国医药工业杂志，2023，54（2）：277-282.

YU Y H，YANG S J，ZHOU B. Brief analysis of priority review of rare disease drugs in China[J]. Chin J Pharm，2023，54（2）：277-282.

王敏，范平安，王志远，等. 美国罕见病药物资格认定及批准上市情况分析[J]. 中国药事，2021，35（12）：1406-1413.

WANG M，FAN P A，WANG Z Y，et al. Analysis of orphan drug designation and marketing approval in the United States[J]. Chin Pharm Aff，2021，35（12）：1406-1413.

刘清扬，刘鑫，王少红，等. 基于《第一批罕见病目录》的罕见病药物可及性研究[J/OL]. 协和医学杂志，2023：1-10[2023-08-23]. https：//kns.cnki.net/kcms/detail/11.5882.R.20230823.1447.002.htmlhttps://kns.cnki.net/kcms/detail/11.5882.R.20230823.1447.002.html.

LIU Q Y，LIU X，WANG S H，et al. Research of accessibility of rare disease drugs based on The First Rare Di- sease Catalogue[J/OL]. Med J Peking Union Med Coll Hosp，2023：1-10[2023-08-23]. https：//kns.cnki.net/kcms/detail/11.5882.R.20230823.1447.002.htmlhttps://kns.cnki.net/kcms/detail/11.5882.R.20230823.1447.002.html.

李亚茹，丁红，苏霞. 罕见病药物研究现状分析与展望[J]. 国际药学研究杂志，2017，44（2）：107-111.

LI Y R，DING H，SU X. Analysis and prospect of status of orphan drug research[J]. J Int Pharm Res，2017，44（2）：107-111.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

中药制剂质量控制研究的发展趋势

基于CNKI高被引论文的近20年中药研究热点与发展趋势分析Δ

Related Author

梁小银陈少旭吴　垠

任永申吕宏宇马艳芹张蓉蓉董旖张萍李燕

Related Institution

No data

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰

Analysis of the marketing of rare disease drugs in China based on the First Batch of Rare Disease Catalog

DOI：10.6039/j.issn.1001-0408.2024.11.02

摘要

Abstract

关键词

Keywords

references